Shalby Limited (SHALBY) Earnings Call Transcript & Summary

November 4, 2026

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 37 min

Earnings Call Speaker Segments

Operator

operator
#1

Elara Capital welcomes you to Shalby Limited's Q2 FY '27 earnings conference call. <<operator_script>> Kindly be aware that this conference is being recorded. At this point, I hand the call to Mr. Kashish Thakur of Elara Capital. Thanks, and the floor is yours, sir. Go ahead.

Kashish Thakur

analyst
#2

Thanks, Shalindar. Good afternoon, everybody. We welcome every participant to the Q2 Financial Year '27 Earnings Call of Shalby Limited, hosted by Elara Securities. Joining us today are senior management representatives from Shalby. We'll begin with performance highlights from Mr. Shanay Shah, President of Shalby Limited, and Mr. Amit Kumar, Group CFO. Following that, we'll open the floor so all the partitions can ask questions and get answers. I'll now pass the call to Mr. Jigar Todi, who has important disclaimers about any forward-looking statements that might be made on today's call. Over to you, Jigar Bhai.

Jigar Todi

executive
#3

Thanks, Kashish. Good afternoon, everyone. Our investor presentation is available on the stock exchange website and on our company website, shalby.org. We hope you have already had a chance to look through the presentation. Please note that some of the statements made on today's call may be forward-looking in nature and may involve risks and uncertainties. Please refer to Slide #2 of the investor presentation for a detailed disclaimer. Now I would like to hand the call over to Mr. Shanay Shah for his opening remarks. Thank you, and over to you.

Shanay Shah

executive
#4

Thank you, Jigar. Good afternoon, everyone, and thanks for being with us. Before I hand things over to our CFO, I'll walk you through the main operational developments for the quarter across our 2 businesses, Shalby Hospitals and Shalby MedTech. Hospitals remain the group's core, and growth this quarter was broad-based. Joint replacement keeps growing and is still our flagship specialty. Other specialties grew faster, especially nephrology and urology, oncology, general surgery and critical care. As a result, our specialty mix is becoming more balanced, which aligns with our strategy of building a multispecialty network and reducing dependence on any single specialty. We keep adding specialist doctors across the network, and this will be a key driver of future growth in the Hospitals business. On the operational side, occupancy improved, average length of stay came down and the share of insured and government scheme patients has gone up. On clinical capabilities, there were a few developments this quarter. Orthopedic continues to establish Shalby as a global center of excellence. This quarter, we treated a member of the family of the Kenya's Chief of Defense Forces for hip Replacement. a former President of Nigeria returned to Shelby for secondly knee replacement 2 years after his first one with us.

Shanay Shah

executive
#5

Nigeria's sitting Vice President also came to a hospital of ours in Ahmedabad to see him. At our SG Highway Hospital in Ahmedabad, we carried out Gujarat's first telerobotic surgery, with the surgeon working remotely out of Gurugram. Robotic surgery keeps growing for us in oncology and urology. Five hospitals now run our transplant program — Ahmedabad, Indore, Jaipur, Surat, Dehli NCR. Kidney transplants are covered, and liver transplants too, including swap procedures and blood group incompatible kidney transplants. We also took on a number of complex referral cases, among them international tons, in neurosurgery and in E&P. On diagnostics, we brought in an advanced infection diagnostics system, the first of its kind in Gujarat, plus liquid-based cytology for cervical cancer cleaning and automated testing that has reduced several report turnaround times from days to hours. Clinical protocols are being standardized throughout the hospital, tightening quality assurance and enhancing the patient journey from admission all the way to post-discharge care. Operations are likewise being integrated more tightly across the network, so that practices that succeed in a better performing hospitals can be copied elsewhere. Operational efficiencies are also being pushed across the hospital business in the first half of the year. These are already visible in several areas of outsourced manpower, and we expect that to keep going.

Shanay Shah

executive
#6

We’ve also launched efforts around materials and consumables, which make up a big portion of what we spend. We anticipate those benefits will begin <<inaudible>> certain hospitals continue to run under their potential. What we’re concentrating on there is getting more out of the infrastructure already in place and enforcing tighter operational discipline, instead of building additional capacity. Shelby International, our Delhi NCR hospital, kept getting markedly better over the quarter. Inside the hospital segment, the Shelby Academy brought in multiple new -- several hundred new students and training this year spanning nursing sister allies and hospital management. That provides us a dependable pipeline of trained staff for our pets. Turning to Shalby MedTech, starting on the commercial side, we’ve begun engaging target surgeons via fellowships, clinical education and product demonstrations, together with in-clinic branding. We moved into the West Bengal and Odisha markets and made our first meaningful showing in Eastern India at AOTS in Kolkata. We’re reigniting Central India, Nagpur and Asam included, with Uttar Pradesh and Uttarakhand coming next. Abroad, we operate in North America, Japan and Indonesia, and we’ve secured approvals from Malaysia, Argentina and Nepal, with additional approvals still in progress. On manufacturing and quality, we’ve raised processing volumes in our clean pack and sterile operations, which boosts product availability.

Shanay Shah

executive
#7

We brought the passivation line back in-house, and we recommissioned the secondary cream line so we could add capacity. Inspection processes have been improved to cut down turnaround times. Quality control nonconformances dropped significantly, first pass acceptance went up, and defects and scrap coming from contract manufacturers were reduced. These steps raise yield and cut rework, and they leave the business better placed to handle higher volumes. At the same time, we're setting up a new supply chain for the MedTech business, and we expect that to substantially lower our cost of goods sold. We expect the benefit to begin accruing in the P&L from quarter 4 of this year, with a full quarter impact coming from quarter 1 of FY '28. So if I have to summarize our priorities for the next half of this fiscal year, they would be: number one, keep adding specialist doctors in the Hospitals business and keep building our capability in the orthopedic and non-orthopedic specialties to drive growth and utilization across the network. The second would be better performance at hospitals that are below their potential, with a focus on asset productivity and operational discipline. At MedTech, the third point would be to complete the transaction to the new supply chain, sustain the quality and capacity improvements, and convert surgeon engagement and new geographies into volumes.

Shanay Shah

executive
#8

Then the fourth item is to keep putting resources into our people, our clinical capabilities, technology, and <<inaudible>>. What we care about is growth that's high quality, running more efficiently, getting more out of our assets, and profitability that can be sustained. Since our major investments are mostly done, we anticipate that CapEx needs will come down from here. Along with the efficiency efforts I just described, that ought to reinforce cash flow further and help us bring debt down over time. With that said, I'll turn things over to our CFO, who will walk you through how we performed financially this quarter.

Amit Kumar

executive
#9

Yes. Thank you, Shanay, and good evening to everybody. Next, I'll take you through how the company performed financially on a consolidated basis in quarter 2 of FY '27. Each figure I mention will be compared year over year — that is, this year's Q2 against Q2 of the prior year. In Q2 of '27, the company posted a healthy improvement across every financial KPI, including the low. Consolidated revenue rose to INR 318 crores, up from INR 290 crores a year earlier, registering growth of approx. EBITDA came in at about INR 46.4 crore versus INR 46.1 crores last year, a rise of 0.8% year on year. The EDITDA margin held firm at about 14.6%, compared with 15.9% in the same quarter a year ago. Consolidated PBT was INR 16.5 crores against INR 19.1 crores in quarter 2 of last year, with a PBT margin of 2.5% -- with a PBT margin of 5.2%. Consolidated PAT grew to INR 7.9 crores, at a PAT margin of 2.5% in quarter 2 of FY '27, versus INR 7.9 crores with a 2.5% PAT margin last year in quarter 2.

Amit Kumar

executive
#10

Our balance sheet is still in good shape, with gearing at 0.45x and net debt at INR 458 crores of drops. It's important to note that net debt has come down this year, and we have strong confidence that we'll see it fall further over the coming quarters. Now, on a stand-alone basis, I'll take you through those same KPIs at the hospital level. Standalone revenue for quarter 2 came in at INR 250 crores versus INR 229 crores last year, which is a strong 9.1% increase year-on-year. EBITDA came in at INR 45.7 crores, compared with INR 44.8 crores last year. The margin stood at 18.2% versus 19.5% in the same quarter a year ago. PBT rose to INR 31.6 crores from INR 30.6 crores last year, with a PBT margin of 12.6%. PAT also increased, to INR 23.5 crores from INR 19.8 crores in quarter 2 of last year. That's a margin of 9.4% versus 8.6% in quarter 2 of last year. At the stand-alone level, debt has likewise come down to INR 14.5 crores from INR 54.5 crores last year.

Amit Kumar

executive
#11

The annualized ROCE is currently at 9.4%. Our ARPOB has risen considerably to INR 42,581, marking a 4.3% increase compared with INR 40,790 core in the prior year. Our loss has likewise come down to 3.58 days versus 3.74 days last year. In addition, our occupancy has climbed to 52%, a gain of 400 basis points, which means 48% in quarter 2 of last year. And excluding our Gurgaon unit, Shalby International, our occupancy has risen to 55% compared with 50% a year ago. The payer mix this quarter stays at roughly 33% Shalby, 38% insurance and approximately 29% in the government peers. Now, importantly, turning to our Gurgaon unit, Shelby International. As long awaited, it has posted very strong growth of about 50% year-on-year in its revenue, but revenue has climbed to INR 30 crore compared with INR 20 crores in quarter 2 of last year. This has shown our strong growth, and we are quite confident that a similar level of growth trajectory will continue in the quarters ahead and the year after. This has been backed by a considerable jump in our ARPOB, which now stands at about INR 96,388, 18% higher than last year, when it was at about INR 81,185.

Amit Kumar

executive
#12

The loss is roughly 300 — the lost handset 3.3 days. Also worth noting, this applies to the Gurgaon unit, which has been EBITDA positive for two quarters in a row and is positive at the H1 level. And at this point we're expecting this unit to reach cash breakeven very soon, likely around the exit of quarter 4. That's backed by better occupancy, higher ARPO, and expanding business on both the domestic and international fronts. Just to note, when comparing our international and domestic growth, the business has expanded on both sides. Measured against last year, the domestic business grew to 56% and the international business grew to about 22%. Turning to our MedTech business, medical implants, our medical implant business in Q2. This is a quarter where our efficiency program began to show the numbers we've been aiming at for a long while. We expect the benefit to build through the remainder of FY '27 as well, with new products, new geography, and a stronger supply chain model already being kicked off in the H2 of this year. Our consolidated revenue now stands at about INR 316 million. SMTL, the parent entity in India, has grown by about 4% to INR 224 million, which reflects growing traction for our products and software execution across India.

Amit Kumar

executive
#13

Entity Inc., our U.S. operation, is likewise holding steady at roughly INR 286 million, up 4% year on year. That comes after a full year of positive EBITDA last year. Once again, the MedTech business posted a positive EBITDA figure — the fifth quarter in a row that MedTech has delivered a positive number. Consolidated EBITDA is now around INR 3.6 million, which is double what it was in the last quarter, when it stood at INR 1.6 million. As was mentioned, our operational efficiencies have begun showing up in Q2, and we expect the full-year benefit to arrive in FY '27. Shanay already briefly touched on our next level of growth, which is gross margin. We have strong confidence in our ability to push it higher from here, with a new supply chain model and steps already underway, and the full benefit should land in Q4 of this year. Beyond that, we anticipate another NPPA price revision, which will lend support to our EBITDA and revenue figures in the India business. On the other side of our inventory, inventory days have dropped 20% year on year over the last 2 years. And it's important to note that in H1, in just those 6 months, they have already come down by 16% and now sit at 784 days, versus about 1,200 days a year earlier.

Amit Kumar

executive
#14

So with that, we're keeping up the same growth momentum, with improved gross margin and operational efficiencies. We think H2 is going to be even more exciting from this point, and we're looking for a stronger year than the prior one. With that said, thank you to our employees, our customers, our business partners and our shareholders. We can now take Q&A.

Operator

operator
#15

<<operator_script>> Our first question comes from Muksh at Prosparity.

Analyst

analyst
#16

This is a question for Mr. Shanay. During the opening remarks, Shanay noted that the hospital segment represents a core business activity and the biggest profit generator, and that is plainly visible at the stand-alone level. So when operations sit at the subsidiary level — especially the implant business acquired in 2021 — you mention that EBITDA there is positive. Yet if we look at PBT, and compare stand-alone PBT with consolidated PBT, over the last 3 years the subsidiary has produced a negative loss of roughly INR 165 crores. Could we instead concentrate on the hospital business and expand it domestically, given that many international players are coming into India? We are very strong in the hospital business. We run the entire hospital profitably — so why are we focusing solely on hospitals rather than diversifying into implants, which contributes nothing positive at the PBT level? Please shed some light on that activity.

Shanay Shah

executive
#17

Yes, and thanks for the feedback and for your question. So look, when you examine the hospital business, it's profitable. It's growing. The underlying potential is solid. We still have a good 50% higher revenue that we can achieve within the existing facilities, which will, of course, bring more than that kind of number trickling down to the EBITDA numbers from the operating leverage that will come in. On the implant side, yes, it has taken us a bit longer, but there have been a lot of positives there. So the cost of manufacturing and implants, when we acquired the facility, was about $1,100, and it has come down by less than half now, and it is going to further come down by an additional 30%, 40% from the current levels with the new supply chain. So the underlying opportunity in that business is also quite strong. And we have prepared a solid base in terms of the new products, the instrumentation that is required, the team that is required to kind of build and grow this business. So we have identified all the capabilities across the different departments. And the positive is that we are not going to deploy a significant amount of new capital in this business because it is going to be health sustaining in a very short period of time.

Shanay Shah

executive
#18

To answer your question, all the extra internal accruals coming in over the upcoming few quarters will go into the hospital business. So whether that means upgrading our facilities, upgrading the technology, or adding beds, the majority — I'd say 80%, 90% of the new capital — is going to be invested in the hospital business. I hope that reassures you.

Analyst

analyst
#19

Yes. I do hold shares in a number of companies, and one of them is an Indian listed firm, specifically TTK Healthcare, which also operates a segment in hip replacement, hip and knee implants, and heart valves — and they earn a solid profit from that business. In our situation, though, we have a USA FDA approval, so we can export from the U.S. to many countries. It is readily accepted in India as well. But we are not — revenue growth has not reached the desired level. And certainly, profit growth has not reached the desired level either. Is something missing, or is it because Vikram bhai is the pioneer in implants, knee replacement, and other procedures? His name alone is sufficient for the hospital business. Why are we focusing solely on the hospital business?

Shanay Shah

executive
#20

To put it plainly, that's precisely the point I was making: all of the new capital — most of it, at least — is going to be directed into the hospital business from here on. And second, regarding the revenue from this business, if I may say so, surgeons in India and abroad have received our products extremely well — not just because it's U.S. <<inaudible>>, but also on account of the design itself. So the thing we're trying to address, and the real obstacle we faced, was the cost of goods, since manufacturing in a country such as the U.S. carries a certain embedded cost. And in high-labor-cost markets like the U.S., there's only so much room to bring that down. So with the new supply chain, we'll begin to benefit from tailwinds — better margins and better growth. And as you said, TTK has been operating in this business for several years, though you'll see in the news that this medical implant sector has drawn interest from plenty of different Indian companies too over the last couple of years.

Shanay Shah

executive
#21

So this comes after the acquisition we made. The timing on that acquisition was truly just right. What it means is that we have to — I mean, as these new costs come in, we'll be in a position to put out a much stronger and better set of numbers. And on top of that, we believe that as we move forward, the bulk of the extra internal accruals are going to go into the hospital business. That comes directly from — this mandate comes straight from the Chairman.

Analyst

analyst
#22

All right. And when would you say the Gurgaon facility will at least start contributing positively at the PBT level?

Amit Kumar

executive
#23

Yes. Amit, <<inaudible>>. Thanks for the question. And if you'd have noticed, revenue at the Gurgaon unit has already jumped by 50%. And that marks the second quarter in a row where EBITDA has been positive. As an effect of Q3 and Q4, we expect it will also reach cash breakeven. Occupancy has begun to grow, and the specialties we're focusing on are giving us a better result. So now it's just a matter of time. The team has delivered a stronger result, and it will continue.

Shanay Shah

executive
#24

On the growth side, let me jump in on that. For us, growth has been running above 50% year over year, correct? And if we get another 20%, 30% of growth from where we are now, we'll be PBT neutral starting from current levels.

Analyst

analyst
#25

Okay. And as for Vikram bhai — and happy Diwali in advance, all the best to the whole team.

Operator

operator
#26

<<operator_script>> Our following question comes from Kashish Thakur with Elara Securities.

Kashish Thakur

analyst
#27

So one question about capping the price of the onco — how are we thinking about that? And what sort of impact might we see, or <<inaudible>> the onco?

Amit Kumar

executive
#28

Yes. Thank you. So this notification came out not long ago and is likely to take effect around mid-November. It concerns roughly 180 molecules, which have already been referenced. Yes, we also use this internally within our onco business. We carried out a high-level analysis, and our margins would not be significantly affected. We are already within the range the government expects, which is about a 30% margin from the MRP. We might see an insignificant sort of impact, but it would not be that large. We are already in line with the expected margin the government is guiding toward.

Kashish Thakur

analyst
#29

Got it. And what sort of likelihood is there that the government — as you folks are hearing, or perhaps as you're getting something ready — might impose some kind of cap on consumables, or on the MedTech business too, which is where we're putting a lot of focus?

Amit Kumar

executive
#30

That isn't likely. Right now, no talks of that kind are taking place. What we do expect, though, is on the plant side: our NPPA hike should land in mid-November, and it has already been owed for the past 2 years — that will provide support to the .

Kashish Thakur

analyst
#31

Got it. One question concerns our expansion...

Shanay Shah

executive
#32

Apologies for cutting in. I'd like to build on what the CFO just mentioned as well. The thing is, the majority of the procedures we perform, oncology included, come as packages. Because of that, the medications aren't sold on a standalone basis. So to that degree, the effect will also drop considerably. Understood.

Kashish Thakur

analyst
#33

Got it. I’ll pivot from my question to the expansion plan. Is there any particular expansion you’d want to share on this call?

Shanay Shah

executive
#34

Yes. So there are a few things. First, we've put a lot into technology. Just one second, sorry, hold on. Yes. So a few points on that. We've made substantial investments in upgrading our technologies, which includes robotics at the majority of our hospitals. We've also brought in high-end radiology equipment such as the linear accelerators, plus other beds and bunkers at additional locations too. We've added a new PET CT scan — a lot of investment in technology over the last 1 year. And we're also looking to use the additional FSI that we have at the Gurugram hospital. So to that extent, we'll be adding more beds, and I think that will be operational within the next 12 to 18 months. So those are largely the expansion plans we have. And of course, there are other avenues we'll be looking at as and when the time comes. At this point, disclosing them may not be the best thing.

Kashish Thakur

analyst
#35

Got it. What are the commissioning timelines looking like for the Mumbai expansion?

Shanay Shah

executive
#36

On the Mumbai expansion, we're essentially collaborating with the trustees. It's been pushed back fairly substantially. A few approvals are still outstanding, and we're coordinating tightly with the trustees. So whenever there's something new, we'll pass it along to you — there isn't really any update on that front at the moment.

Kashish Thakur

analyst
#37

Got it. And finally, on FOSO, what type of revenue does that side of the business bring in?

Shanay Shah

executive
#38

Our focus is solely on FOSOs that are profitable, and we've restricted our operations to those profitable FOSOs. The financial KPI isn't the only thing we examine — the quality KPI matters too. So we are selective in this regard. If you ask us, we have an aggressive plan there. So no. We're only concentrating on building our in-house capacity and on selective FOSOs only.

Operator

operator
#39

The next question comes from Suraj at Kuglimited.

Analyst

analyst
#40

My question relates to the MedTech business. We bought this in 2021, and it was afterward that we got the target stabilized quite well. Now I'd like to get a sense of what the road map looks like for this company over the next 2 to 3 years — from a top line standpoint, from an EBITDA standpoint, and from a debt standpoint as well, if you could shed some light on that, Mr. Shanay.

Shanay Shah

executive
#41

Right. So with the new supply chain in place, costs are going to drop a lot. And then we'll push hard on sales, because profitability is going to be higher. We expect sales to rise quite substantially over the next couple of months, and that growth will show up gradually. So I can't give you numbers, because we're not — I mean, we do have projections internally, but we're not in a position to share them. But yes, on that side as well, in the implant business, we're going to see a meaningful reduction in debt. The reason is that we'll be drawing down our existing inventory. So if you look at the last 6 months, sales have also increased, yet absolute inventory has fallen. So from roughly 1,200 to 1,500 days of inventory, we've cut it in half. So I think that's really the direction we're headed. We're trying to bring inventory days down significantly, lift profitability and improve cash flow — and cash flow will get better if we don't add substantially to new product pipelines, et cetera.

Shanay Shah

executive
#42

Right now, we don't have plans to bring in a large number of new products. The ones already in development will obviously still launch, but beyond that, we won't be adding many products. So with all of that in place, we're on the right path toward growing sales, boosting profitability, bringing inventory down, and improving cash flow.

Analyst

analyst
#43

Sure. Could you provide a number for the debt you expect in the implant business over the next 1 or 1.5 years — how much it might come down by?

Shanay Shah

executive
#44

What we think is that debt on a consolidated basis is going to drop meaningfully, for the reason that this is beyond what you'd have observed. Over the past many quarters, this marks the first occasion on which we've recorded a decline in overall net debt. So that debt will keep shrinking as we move ahead. And at a considerably quicker rate once the new supply chain comes in, though I'll let — I'll ask our CFO to shed further light on that.

Amit Kumar

executive
#45

Yes. Thank you, Shanay. Turning to the debt — as Shanay noted and as I said earlier, the debt went down during this quarter. And that happened even though the dollar grew stronger; if the dollar had stayed at that same level, the reduction in debt would have been even greater. As for the quarters ahead, when we say it will come down, that is also backed by the fact that the PK has turned EBITDA positive. The cash needs there have dropped significantly. The MedTech asset overall has now marked a fifth consecutive year of EBITDA positive. Its EBITDA roughly doubled in the prior quarter. Their cash needs have come down relatively. At the group level, our cash flow requirement has been so low that, if I give you a figure, it was only INR 10 crore of CapEx, which we spent this year on replacement, versus the INR 160 crore of CapEx that we spent last year. So with these numbers, our cash flow needs and cash accruals should be much higher, which will bring this debt down, and we are confident. It is hard to predict the number, but you will see it steadily decline over the coming quarters.

Operator

operator
#46

<<operator_script>> Our following question comes from Kashish Thakur with Elara Securities.

Kashish Thakur

analyst
#47

Sir, a question on the bookkeeping side. What level of CapEx should we be looking at for FY '27? And second, what tax rate ought we to expect for FY '27?

Shanay Shah

executive
#48

CapEx during H1 came to roughly INR 10 crores. And in H2 as well, we're not looking at an insignificant figure. What's needed is basically replacement spending to maintain the business's health and the medical equipment that's essential to the hospital. We aren't anticipating any major CapEx. Beyond that, MedTech is already well resourced for CapEx this year. Turning to the tax rate, it's now considerably better. At the stand-alone level the tax rate sits at just 25%. We have that versus 35% a year ago. If you look, our ATR has dropped notably now — last year it was around 65%, and now it's roughly 49%. That's another factor that will give us support on cash flow going forward.

Kashish Thakur

analyst
#49

Is there any guidance you can share toward that figure for FY '27?

Shanay Shah

executive
#50

Regarding — in terms of what?

Kashish Thakur

analyst
#51

ATR?

Shanay Shah

executive
#52

That would be roughly 45% lower in the ring. At 50%, it has already decreased, and there might be a bit more of a reduction as EBITDA and profitability improve at the PK Gurgaon unit and on the MedTech side.

Surya Patra

analyst
#53

Got it. And is there any guidance you'd be willing to share regarding margins or the top line for FY '27?

Shanay Shah

executive
#54

We're expecting double-digit growth on the top line, and that's already in place by the H1 — as you've seen, it's nearly there already. Hospital has turned around quite strongly in the H1 compared with the prior year. The MedTech CAGR had also been running at about 40%, 50% into the recent year. We're trying to keep up that same momentum. So double-digit growth is very much supported by the confidence we have in H2. And on the EBITDA side as well, since all the units, all the entities are now EBITDA positive, you would definitely see a relatively better EBITDA margin than the previous year, and it would also bounce strongly further in the coming quarter of the next year.

Operator

operator
#55

Thank you. With no more questions from the audience, I'll turn the conference back to management so they can offer their closing remarks.

Executive

executive
#56

Thanks to all of you for being on this call. We'll be speaking with each other once more when the next quarter comes around. Beyond that, should anything come up that you'd like to ask about, feel free to contact us at our investor e-mail ID. Thank you. Happy Diwali.

Operator

operator
#57

Appreciate it. That wraps up this conference on behalf of Flare Capital. Thanks for being with us — you can go ahead and disconnect your lines now. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Shalby Limited transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Shalby Limited earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Shalby Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.